Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 1
Abstract
Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from individualized treatment. In addition, they help to enable the prediction of prognosis, the detection of early therapeutic and adverse effects, and may serve as surrogate endpoints in clinical trials. BM are becoming essential tools to increase productivity in drug discovery and impressively enhance the way medicine is practiced. However, the identification, sufficient validation and implementation of such BM are challenging. This process requires expertise from different areas and high resource investments. Collaborations of different partners may be helpful to overcome these challenges. In the past decade, collaborations between diagnostics and pharmaceutical companies as well as industrial–academic collaborations have been increasingly pursued. Moreover, public funding may offer support and open new opportunities to form such consortia. Herein we give an overview of the different types of collaborations, their opportunities and challenges, and describe experiences in forming strategic partnerships with other companies.
Authors and Affiliations
Lilla Landeck, Monika Lessl, Joachim Reischl, Andreas Busch, Patricia Carrigan, Matthias Gottwald, Petra Reinke4 and Khusru Asadullah
Keywords
Related Articles
- EP ID EP679277
- DOI -
- Views 181
- Downloads 0
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...
Prioritization of COPD protein biomarkers, based on a systematic study of the literature
Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease mostly due to smoking and until now diagnosed by spirometry (post bronchodilator FEV1/FVC <70%). However, in spite of the usefulness of FEV1 as diagn...
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
The SMART healthcare solution
Substitutable Medical Apps Reusable Technologies (SMART®) on Fast Healthcare Interoperability Resources (FHIR) is an open, standards platform that allows third parties to build health applications that interact with elec...
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...